Vivos Therapeutics Inc. (VVOS)
| Bid | 3.4 |
| Market Cap | 20.55M |
| Revenue (ttm) | 12.98M |
| Net Income (ttm) | -11.19M |
| EPS (ttm) | -4.99 |
| PE Ratio (ttm) | -0.7 |
| Forward PE | -2.93 |
| Analyst | Buy |
| Ask | 3.73 |
| Volume | 65,105 |
| Avg. Volume (20D) | 204,938 |
| Open | 3.64 |
| Previous Close | 3.71 |
| Day's Range | 3.40 - 3.77 |
| 52-Week Range | 1.91 - 6.28 |
| Beta | 7.44 |
About VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening ...
Analyst Forecast
According to 2 analyst ratings, the average rating for VVOS stock is "Buy." The 12-month stock price forecast is $6.3, which is an increase of 80.52% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · proactiveinvestors.com
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic allianceVivos Therapeutics (NASDAQ:VVOS) announced an expansion of its strategic marketing and distribution alliance with Rebis Health into two additional locations in Colorado. The company said initial data ...
